bioMérieux S.A. (BMXXY) Stock Price & Analysis
bioMérieux S.A. (BMXXY) — price $10.20 (+0.05%), as of the Nov 19, 2026 trading session; market cap $12.0B.
Educational signal · not a buy or sell recommendation · How to read this
bioMérieux S.A. · BMXXY · Healthcare · Medical - Diagnostics & Research
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.20 | |
| Change on the day | +0.05% | |
| 52-week range | $7.12–$14.55 | |
| Market capitalisation | $12.0B | — |
| Price / earnings (trailing) | 23.07 | |
| Shares traded on the day | 300 | |
| Beta (volatility vs the S&P 500) | 0.62 | |
| Dividends per share (last 12 months) | $0.11 | |
| Dividend yield (last 12 months) | 1.11% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for bioMérieux (BMXXY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is bioMérieux (BMXXY), and what does it report?
Short answer · as of
The business analyzes biological specimens for infectious diseases, cardiovascular conditions and cancers, while also serving quality-control facilities in food, pharmaceuticals, cosmetics and veterinary markets.
Research dated 2026-09-13.
Hospital laboratories, medical practitioners and blood banks therefore sit beside industrial customers in its demand base.
Reported revenue captures a broader activity set than clinical diagnostics alone. The distinguishing feature is the combination of patient testing and manufacturing microbiology, which exposes bioMérieux to laboratory testing volumes as well as quality-control activity across regulated production environments.
What do the latest results show for bioMérieux (BMXXY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €1.96B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.36B Mar 5, 2026
- Latest report · revenue estimate
- $1.11B Mar 5, 2026
- Latest report · revenue vs estimate
- Above estimate Mar 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Mar 5, 2026 | $2.36B | $1.11B | $0.2302 | Not available |
| Sep 4, 2025 | $2.41B | $1.32B | $0.1594 | Not available |
| Mar 7, 2025 | $2.15B | $1.24B | $0.1891 | Not available |
| Oct 30, 2024 | $2.04B | $1.04B | $0.1952 | Not available |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €1.96B | €226M | €0.19 (diluted) |
| Q4 FY2025 | €2.01B | €235M | €0.20 (diluted) |
| Q2 FY2025 | €2.04B | €161M | €0.14 (diluted) |
| Q4 FY2024 | €2.08B | €217M | €0.18 (diluted) |
What are the financial strengths and risks for bioMérieux (BMXXY)?
Short answer · as of
The distress and quality screens read Altman Z 6.09 · Piotroski F 7. Trailing ratios: ROE 11.0% · ROA 8.1% · current ratio 2.30 · earnings yield 4.2% · free-cash-flow yield 5.4%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BMXXY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BMXXY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About BMXXY (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does bioMérieux sell to hospital laboratories and industrial control facilities?
bioMérieux provides diagnostic platforms that analyze biological specimens in clinical settings and microbiological tests used for manufacturing quality control. Its customer base therefore extends from hospitals and blood banks to regulated industrial facilities.
Is bioMérieux mainly an infectious-disease testing company?
Infectious-disease detection is central, but the portfolio also addresses cardiovascular conditions, cancers and microbiological quality control. Industrial applications make the company broader than a clinical infectious-disease specialist.
What is the BMXXY stock price today?
The last price recorded for bioMérieux S.A. (BMXXY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does BMXXY pay a dividend?
Yes. The dividend yield of bioMérieux S.A. (BMXXY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 31 figures on this page — 25 from Financial Modeling Prep (FMP), 3 with no recorded source and 3 computed by us, formula shown in the register. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com